PALO ALTO, Calif., Sept. 2, 2004 (PRIMEZONE) -- Today, 7 million persons (one out of every 40) in the U.S. are afflicted with Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS - Lou Gehrig's Disease), Multiple Sclerosis (MS), or other neurodegenerative diseases. It could take 10 or 20 years, or more, to find cures for these horrible illnesses. However, there may be a much shorter path to cures that benefit patients, opening a multi-billion-dollar marketplace for innovative biotech and pharmaceutical companies.
The potential is described in a new Webcast series produced by Killen & Associates. The series is titled "The Neurodegenerative Disease Market: Opportunities to Solve the Mysteries of Alzheimer's, Parkinson's, ALS, and Other Devastating Illnesses." (Go to http://www.killen.com/ndd/trailer to view a multimedia trailer of the series.)
The Webcasts feature four noted experts who describe the common underlying mechanisms of illnesses such as Alzheimer's, Parkinson's, ALS and MS. Their insights create a foundation for envisioning how biotech and pharmaceutical firms can shorten the time to find cures by leveraging the common elements of these neurodegenerative diseases. Firms that make breakthroughs in one disease area may have the technology necessary to open doors to other neurodegenerative disease markets as well.
The Webcast series will be available for general viewing on September 8, 2004 at http://www.killen.com/ndd.